Preliminary results of investigation regarding influence of sacubitril/valsartan supramolecular complex on healthcare resource consumption

Chronic heart failure (CHF) is a disease characterized by a number of typical symptoms, which are related to inadequate blood perfusion of internal organs both at rest and under exercise, which often also leads to liquid retention. It has poor prognosis and constitutes considerable burden on healthcare system. Supramolecular sacubitril/valsartan complex has been shown to significantly reduce frequency of hospitalization and emergency room visits in international RCT's. This indicates that there is a significant interest in performing local, Russian studies focusing on effects of using sacubitril/valsartan may have on healthcare system burden. Methodology. Epidemiological characteristics of patients with CHF receiving “standard” care were assessed. 75 healthcare professionals have been questionnaired to investigate patient parameters and significant event frequency. The study was carried out in 10 large cities of Russian Federation. Effects of switching patients to the new therapy were also assessed. Results. It was confirmed that epidemiological properties of patient population is within parameters found during previous large Russian epidemiological studies. It was found that utilization of sacubitril/valsartan is associated with significant reduction in healthcare resource utilization due to reduction in hospitalizations and emergency service use. Per 3 month of observation, patients receiving standard treatment had average hospitalization frequency of 0,8 and a similar frequency of requiring ambulance dispatch. Switching patients to sacubitril/valsartan resulted in drop of hospitalization frequency to 0,3 (per 3 month of observation) and a similar reduction of ambulance calls. Conclusions. Preliminary analysis of data obtained during this study confirms high efficacy of new therapy using sacubitril/valsartan supramolecular complex within Russian healthcare, specifically regarding reduction of clinically significant unfavorable events such as hospitalizations and ambulance calls. This indicates that this treatment approach has potentially beneficial effect on burden experienced by medical facilities and expedience of carrying out further research in this direction.

сакубитрил валсартан, хроническая сердечная недостаточность, ингибитор ангиотензиновых рецепторов и неприлизина, АРНИ, потребление ресурсов здравоохранения, госпитализация, sacubitril/valsartan, chronic heart failure, ARNI, consumption of healthcare resources, hospitalization

1. Bonneux L., Barendregt J.J., Meeter K., et al. Estimating clinical morbidity due to ischemic heart disease and congestive heart failure: the future rise of heart failure. Am J Public Health 1994; 84: 20.

2. Desai A.S., Claggett B.L., Packer M. et al. PARADIGM-HF Investigators. Influence of sacubitril/valsartan (LCZ696) on 30-Day readmission after heart failure hospitalization. J Am Coll Cardiol. 2016; 68: 241-248.

3. McMurray J.J., Packer M., Desai A.S., PARADIGM-HF Investigators and Committees Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371: 993-1004.

4. Ponikowski P., Voors A.A., Anker S.D., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37: 2129.

5. Арутюнов А.Г., Драгунов Д.О., Арутюнов Г.П., Рылова А.К., Пашкевич Д.Д., Витер К.В., и др. Первое открытое исследование синдрома острой декомпенсации сердечной недостаточности и сопутствующих заболеваний в Российской Федерации. Независимый регистр ОРАКУЛ-РФ. Кардиология. 2015; 55 (5): 12-21.

6. Беленков Ю.Н., Фомин И.В., Мареев В.Ю., Агеев Ф.Т., Бадин Ю.В., Галявич А.С., и др. Распространённость хронической сердечной недостаточности в Европейской части Российской Федерации данные ЭПОХА - ХСН (часть 2). Журнал Сердечная недостаточность. 2006; 7 (3): 3-7.

7. Горохова С.Г. и др. О бремени сердечной недостаточности в России. Лечебное дело. 2014; 3: 28-32.

8. Карпов Ю.А., Сорокин Е.В. Антагонисты минералокортикоидных рецепторов при хронической сердечной недостаточности: показания к назначению и выбор препарата в свете современных знаний. Атмосфера. Новости кардиологии. 2015; 1: 21-26.

9. Клинические рекомендации ОССН и РКО. Хроническая сердечная недостаточность (2016 г.). [Электронный ресурс] URL: http://ossn.ru/news/klinicheskie-rekomendatsii-khronicheskaya-serdechnaya-nedostatochnost/ (дата обращения: 01.12.2017).

10. Фомин И.В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016; (8): 7 -13. D0I: 10.15829/1560-4071-2016-8-7-13.

11. Pitt B., White H., Nicolau J. et al.; EPHESUS Investigators. Eplerenone reduced mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005; 46: 425-431.

12. Zannad F., McMurray J.J.V., Henry Krum H. et al. for the EMPHASIS-HF Study Group. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med. 2011; 364: 11-21.